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Highlights  
 
• We assess opioid and dopamine control of food intake with two cost/benefit decision-making 
tasks 
• Naloxone reduces operant responses for palatable food without affecting free chow intake  
• Haloperidol shifts behavior away from lever pressing and increases free chow feeding 
• Naloxone reduces preference for palatable banana pellets when no effort is involved  
• Dopamine antagonism reduces intake of both foods without altering preference  
  
Abstract  
Eating disorders are associated with impaired decision-making and dysfunctional reward-related 
neurochemistry. The present study examined the potential contributions of dopamine and opioid 
signaling to these processes using two different decision-making tasks. In one task, Long Evans 
Rats chose between working for a preferred food (high-carbohydrate banana-flavored sucrose 
pellets) by lever pressing on a progressive-ratio schedule of reinforcement vs. obtaining less 
preferred laboratory chow that was concurrently available. In a second (effort-free) task, rats 
chose between the same two reinforcers when they were both available freely. Rats were trained 
in these tasks before receiving haloperidol (0.00, 0.05, 0.10 mg/kg, intraperitoneally (i.p.)) or 
naloxone (0.0, 1.5, 3.0 mg/kg, i.p.). In the first task, haloperidol decreased breakpoint, lever 
presses, number of reinforcers earned, and increased chow intake, whereas naloxone decreased 
breakpoint and number of reinforcers earned but had no effect on chow consumption. In the 
effort-free task, haloperidol reduced intakes of both foods without affecting preference, whereas 
naloxone selectively reduced the consumption of banana-pellets. The present findings support 
converging evidence suggesting that DA signaling affects processes more closely related to 
appetitive motivation, leaving other components of motivation unchanged. By contrast, opioid 
signaling appears to mediate aspects of hedonic feeding by selectively altering intakes of highly 
palatable foods. For preferred foods, both appetitive and consummatory aspects of food intake 
were altered by opioid receptor antagonism. Our findings argue against a general suppression of 
appetite by either compound, as appetite manipulations have been shown to unselectively alter 
intakes of both types of food regardless of the task employed.  
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1. Introduction  
 
Binge eating and related food-centered pathologies are marked by a number of behavioral 
and cognitive symptoms. Among these are intense cravings, recurring bouts of elevated intake of 
highly palatable foods, loss of control, and the transition from normal consumption patterns to 
more compulsive-like behaviors [1]. Often, these episodes can reach such intensities that they 
impair normal decision-making processes and lead to behaviors that mimic those seen during 
cases of drug addiction [2–6]. Proper treatment of these disorders has become a challenge for 
clinicians because of their complexity in etiology and presentation. Given the wide range of 
genetic, biological, and socio-cultural determinants that contribute to disordered eating, it is not 
likely that a single factor is solely responsible for the development of these disorders. Because of 
this, it has become increasingly important to develop partial animal models that assess specific 
behaviors/symptoms and their underlying neurochemical signatures. Of special credence is the 
contribution of dysregulated reward-related process and decision-making impairments [4]. 
Those diagnosed with eating disorders often have difficulties with decision-making that 
requires assessing different behavioral options based on their respective costs and benefits. 
Because of this, it has been suggested that food based decision-making tests are well suited to 
model a number of these cognitive, appetitive, and consummatory behaviors in rodents [7,8]. 
One type of decision-making that merits considerable attention involves situations where 
organisms must choose between simple actions that yield smaller less desired rewards, or 
behaviors that result in higher valued options but require significantly more effort. In these tasks, 
rats choose between a low effort/low reward option (freely available) standard laboratory chow 
and a higher effort/high reward option (lever pressing to obtain more palatable sucrose pellets).  
Eating is controlled by many areas of the brain and neurotransmitter systems involved in 
motivation, hedonic processing, learning and memory, and homeostatic regulation [for detailed 
reviews see [9–11]]. For these reasons, it is important to narrow the focus to specific 
neurotransmitter systems and their dissociated contributions to food motivation. The use of the 
aforementioned behavioral paradigms in conjunction with pharmacological tools has made it 
possible  to observe the effects of certain manipulations on consummatory and appetitive 
behaviors independently, and determine precise neurochemical contributions that contribute to 
these various aspects of food intake and food-related decision-making.  
The endogenous opioid system (EOS) consists of a number of opioid peptides and their 
respective receptors, distributed throughout a number of central and peripheral tissues [12–15]. 
EOS involvement in a number of biological processes that include analgesia, hormone 
regulation, motor function, motivation, and hedonic processing can likely be attributed to their 
vast localization in the brain and periphery [10,16,17]. In addition to these functions, opioid 
regulation of food intake has also been greatly studied. Opioids have been found to affect the 
hedonic processing of palatable foods in both rodents and humans [18–23]. Studies using the 
taste reactivity test, a well validated measure of hedonic responses [16,24,25], have found that 
opioid stimulation of discrete hedonic spots within the nucleus accumbens (NAc), ventral 
pallidum (VP) increases facial reactions associated with positive affect that arise from ingestion 
of sweet palatable solutions [26–28].  
It has also been suggested that opioids mediate eating that occurs outside of caloric 
needs, or hedonic feeding [19,29,30].  Opioid receptor agonists tend to produce increases in food 
intake in animals while opioid receptor antagonists mostly show inhibitory effects [31–33], but 
these affects appear to be sensitive to the overall palatability of the reinforcer. Although opioid 
  
agonists and antagonists can affect the intakes of normal foods at higher doses or when those 
foods are presented alone, their effects are more pronounced on foods that rate higher in 
palatability, such as those high in fat or rich in carbohydrates [34–38]. It has been then suggested 
the EOS is likely responsible for regulating intakes of particular macronutrients [39–41]. 
However, further studies have found that what seems to be important is not a specific 
macronutrient, but rather the baseline preference of the animal [42–44]. Organisms that prefer 
foods high in fats will selectively decrease their intake of such foods upon administration of 
opioid receptor antagonists, and those that prefer high carbohydrate foods will alter their intake 
of carbohydrates. This baseline preference is also correlated with opioid agonists and antagonists 
ability to alter taste reactivity [45,46]. 
Opioid agonists and antagonists have also been shown to affect an animal’s willingness 
to engage in operant behavior [38,47,48], suggesting the EOS goes beyond the processing of the 
hedonic value of food to also include the motivation to engage in food-reinforced behaviors. 
These studies have mostly focused on operant actions when a single food option is available. 
Despite the vast amount of literature devoted to opioid regulation of food intake, it is not well-
understood how disruptions to this system affect certain aspects of decision-making and food 
preference. To this end, the present study was designed to investigate the role of the endogenous 
opioid system in food preference using two different decision-making tasks. In order to gauge 
animal’s baseline preference of sucrose pellets to standard laboratory chow, we employed a 
traditional preference test in which both food options were available concurrently. In the other 
task (progressive ratio/chow feeding or effort condition), animals were given the option of 
obtaining less palatable laboratory chow that was freely available in the chamber vs. working for 
a preferred food (high-carbohydrate banana-flavored sucrose pellet) by lever pressing on a 
progressive ratio (PR) schedule of reinforcement, in which the work requirements increased 
systematically with each food reinforcer earned.  This task was adapted from Salamone and 
colleagues, originally developed to describe how dopaminergic modulations can affect some 
aspects of food motivation while leaving others unchanged [49]. Given that dopaminergic 
involvement in these processes has been greatly characterized [For review see [50,51], we 
compared the effects of systemic dopamine antagonism to those produced by administration of a 
nonselective opioid receptor antagonist, naloxone.  
 
2. Materials and Methods  
 
2.1 Animals 
  
 Adult male Long Evans rats (n = 8) were supplied from Harlan (Indianapolis, IN) and 
housed in pairs within a temperature controlled (22± 2° C) room on a standardized 12h light/dark 
cycle (lights on at 7:00 AM). Animals were food restricted throughout the experiment to 
approximately 85% of their free-feeding weight, and had access to water ad libitum. Rats were 
allowed to consume all food obtained during behavioral tests. They were also given additional 
access to laboratory chow (Lab Diet 5012, St. Louis, MO) and allowed modest weight gain 
throughout the duration of the experiment. All procedures were conducted in accordance with the 
Institutional Animal Care and Use Guidelines of Reed College and the National Institute of 
Health (NIH) guidelines for the Care and Use of Laboratory Animals.  
 
2.2 Pharmacological Agents  
  
 
 Haloperidol was purchased from Sigma Aldrich (St. Louis, MO) and dissolved in a 0.3% 
tartaric acid solution. Microliter quantities of 1.0M NaOH were titrated into all solutions to 
rescue pH (4.0). The 0.3% tartaric solution served as the vehicle control for this condition. 
Naloxone hydrochloride was obtained from Sigma Aldrich Co. (St. Louis, MO) and prepared in 
a 0.9% saline solution. Saline served as the vehicle control for all naloxone experiments. Doses 
of haloperidol and naloxone were selected from previously published data [52–55]. All injections 
were delivered intraperitoneally (IP).  
 
2.3 Decision-making Task  
 The basic decision-making task was adapted and modified from those created by 
Salamone and colleagues [53]. Operant sessions were conducted in two-lever operant chambers 
(27 cm length x 30 cm width x 29 cm height; Med-Associates, St. Albans City, VT). All tasks 
were programmed and executed on a 512KE PC using Med-PC software. Behavioral and 
pharmacological testing occurred Monday through Friday between 11:30 AM and 1:30 PM and 
sessions were 30 min long. Rats received a single day of magazine training in which 45 mg 
banana-flavored sucrose pellets (Bio-Serv; Frenchtown, NJ; 3.90 kcal/gm; 0% Protein, 0% Fat, 
0% Fiber, 97.5% Carbohydrate) were delivered irrespective of responding every 30 s (i.e., a 
fixed-time [FT] 30-s schedule of delivery). Animals were then trained to press a lever on a 
continuous schedule of reinforcement (i.e., fixed-ratio [FR] 1) for 5 sessions before switching to 
a PR schedule. For PR sessions, the ratio began at 1 FR1 and increased by 1 response every 15 
reinforcers (FR 1 x 15, FR 2 x 15, FR 3 x 15, etc). Training sessions were conducted 5 days per 
week for 5 weeks (25 total sessions) until responding reached a steady state, defined by 
variability no greater than 15% across sessions and the absence of monotonic trends (confirmed 
statistically using  one-way Analysis of Variance (ANOVA)).  At this point, lab chow (Lab Diet 
5012; St. Louis, MO; 3.07 kcal/gm; 27.0% Protein, 13.1% Fat, 59.9% Carbohydrates) was 
introduced concurrently in the chamber with the PR schedule.  For this PR/Chow training, 15-20 
g of lab chow was weighed and placed in a small, glass, petri dish that was subsequently 
positioned in the far corner of the operant chamber, underneath the unused left lever.  Rats were 
removed after each 30-min session and chow intake was measured, including any spillage. 
Training continued for another 4 weeks (24 Total sessions) until the same previously defined 
stability criteria was established and pharmacological testing began. All pharmacological testing 
for haloperidol happened first. Animals were then given a week off of pharmacology but 
continued baseline training and were then tested in naloxone.  
 
2.4 No Effort Intake Test  
 Food preference in a free feeding situation (30-min sessions; 5 days per week) was 
assessed in the same group of animals after the conclusion of the PR/Chow phase of the 
experiment.  All sessions were conducted in the same operant chambers previously described.  
One rat developed respiratory issues at the beginning of the experiment and its data were 
removed from all further analyses.  Prior to a session, 15-20 g of chow and 20-25 g of banana 
pellets were weighed onto glass petri dishes and placed within the operant chambers. Dish 
locations coincided with the position of the left and right levers, and location was 
counterbalanced across individuals. Rats were placed in their respective operant chambers, the 
house light was turned on, and a timer ran down the 30-min sessions. Animals were then 
removed and consumption of both food options was measured, including spillage. Preference 
  
training occurred 5 days a week and continued for 2 weeks (10 sessions total) until consumption 
reached stable conditions. Stability was defined as defined as before, and statistically confirmed 
using one-way ANOVA (factor: session). Pharmacological testing for naloxone occurred first on 
the no effort intake test. Animals continued baseline training for a week without any drug 
treatments and were then tested with haloperidol.  
 
2.5 Experimental Procedures  
All experiments used a within-subject design in which each rat received all treatments.  
Animals received each dose of drug (IP) a single time.  For PR/Chow testing, drug was 
administered on Fridays, with doses counterbalanced across individuals.  Rats continued baseline 
training from Monday through Thursday. Drug testing was conducted on Tuesdays and Fridays 
for all no effort assessments. The change in drug treatment was justified by the relatively short 
half-life and action of both compounds [56,57].  Off days were dedicated to additional baseline 
preference training.  
 
2.5.1 Effects of Opioid Receptor Antagonism on PR/Chow Responding: Comparison to DA 
Antagonism  
 
 Experiment 1 assessed the effects of the dopamine D2 receptor antagonist haloperidol on 
PR/Chow performance. Baseline training continued four days a week, and behavioral 
performance was unaffected by any previous injection. On drug days, rats received IP injections 
of 0.05 mg/kg haloperidol, 0.10 mg/kg haloperidol, or vehicle 50 min before PR/Chow testing.  
Experiment 2 explored the role of the nonselective opioid receptor antagonist naloxone 
on PR/Chow responding. Animals were given a week off from pharmacology at the conclusion 
of the first experiment but continued baseline training. Rats received IP injections (saline, 1.5 
mg/kg, or 3.0 mg/kg) 30 min before testing began.  
 
2.5.2 Effects of Opioid Receptor Antagonism on Food Preference: Comparison to DA 
Antagonism  
Experiment 3 measured the effects of systemic haloperidol on food preference in a free 
feeding situation. Animals underwent preference training after the conclusion of Experiment 2 
until intakes stabilized. IP injections (0 mg/kg or 0.10 mg/kg haloperidol) were administered to 
each animals 50 min before each test.  
Experiment 4 was carried out to explore the effects of systemic naloxone on food 
preference. Rats were given a week off from pharmacological testing after the conclusion of 
Experiment 3 but continued baseline training. They received naloxone (0.0 mg/kg or 3.0 mg/kg) 
30 min before behavioral testing.  
 
2.6 Statistical Analysis  
The effects of haloperidol and naloxone on breakpoint, number of lever presses, number 
of reinforcers, banana pellet intake (calories) and chow intake (in grams and calories), and total 
intakes (in calories) during PR/Chow sessions were recorded using Med-PC software and 
analyzed using a one-way repeated measures ANOVA. Post hoc Tukey HSD tests were 
conducted when ANOVA indicated significance. For preference tests, the effects of naloxone 
and haloperidol on intake, in grams and calories, were analyzed using two-way repeated 
measures ANOVAs followed by Tukey Tests when necessary. Stability on measures of 
  
breakpoint, lever pressing, reinforcers, and chow intake on the PR/Chow test was determined 
using one-way repeated measures ANOVA. For the no effort intake test, stability was 
determined using a 2 x 2 repeated measures ANOVA. All statistical analyses were carried out 
using STATA SE 13.0 (College Station, TX). 
 
3. Results  
 
3.1 Baseline behavioral training  
 
 Animals went through extensive training before any sort of pharmacological testing 
occurred. Rats were first trained to respond on a PR schedule of reinforcement alone until 
behavior was stabilized and chow was introduced into the chamber. Stable performance on the 
PR schedule was statistically confirmed using one-way repeated measures ANOVA on measures 
of breakpoint, lever presses, and number of reinforcers earned over the last four days of testing. 
ANOVA revealed no differences in breakpoints [F(3,18) = 2.11, n.s], lever presses [F(3,18) = 
2.59], or number of reinforcers earned [F(3,18) = 0.59, n.s] over the last four days of training. 
Introducing chow into the chamber affected lever pressing measures but overall did not affect the 
overall intakes of the animals tested. We compared performance on the PR task and PR/Chow 
Task on a number measures when behavior was stabilized. Dependent measures t-tests showed 
that the addition of chow decreased lever pressing on the PR schedule [t(6) = 6.463, p < 0.05, 2-
tailed], but had no affect on the animals total intakes in either calories [t(6) = 0.5457, n.s] or 
grams [t(6) = 0.59, n.s].  
 We also assessed stability on the concurrent feeding PR/Chow procedure using separate 
one-way (factor: session) repeated measures ANOVA on breakpoint, lever pressing, number of 
reinforcers, and chow intake over the last four days of training. ANOVA revealed no significant 
effect of day on breakpoint [F(3,18) = 0.74, n.s], number of lever presses [F(3,18) = 0.92, n.s], 
number of reinforcers earned [F(3,18) = 0.62, n.s], or chow consumption [F(3,18) = 1.27, n.s], 
further suggesting performance had reached stable levels. 
 
3.2 Experiment 1: Effects of systemic haloperidol on PR/Chow Performance  
   
The first experiment analyzed the effects of haloperidol administration on PR/Chow 
performance. Results from the first experiment can be seen in Figure 1. The repeated measures 
one-way (factor: haloperidol dose) ANOVA revealed that haloperidol reduced breakpoints 
[F(2,12) = 14.04, p < 0.05, see Figure 1A] in drug treated rats. Post hoc Tukey tests indicated 
both 0.05 mg/kg (M = 2.86, SEM = 0.46) and 0.10 mg/kg (M = 1.57, SEM = 0.20) differed (p < 
0.05) from the vehicle condition (M = 6.29, SEM = 1.19). Haloperidol reduced the number of 
lever presses [(F(2,12) = 6.70, p < 0.05, see Figure 1B]. Both doses tested, 0.05 mg/kg (M = 
75.14, SEM = 25.17) and 0.10 mg/kg (M = 20.43, SEM = 5.11) significantly attenuated lever 
pressing compared to vehicle (M = 360.6, SEM = 129.9), (p < 0.05). Dopamine D2 receptor 
antagonism also decreased the number of reinforcers earned [F(2,12) = 14.46, p < 0.05, see 
Figure 1C]. Tukey’s test showed that both 0.05 mg/kg (M = 34.00, SEM = 7.05) and 0.10 mg/kg 
(M = 15.14, SEM = 3.03) doses differed significantly (p < 0.05) from vehicle (M = 83.86, SEM = 
17.53), but no differences were found in reinforcer attainment between mid and high doses. 
Finally, systemic administration of haloperidol resulted in marked increases in chow intake 
[F(2,12) = 17.51, p < 0.001, see Figure 1D]. Increases in chow consumption (p < 0.05) were seen 
  
at both 0.05 mg/kg (M = 7.85, SEM = 0.77) and 0.10 mg/kg (M = 8.84, SEM = 0.47) haloperidol 
doses compared to vehicle (M = 6.03, SEM = 0.70). 
 Due to the differences in energy density between the two reinforcer types, we compared 
the effects of haloperidol treatment on banana pellet, chow, and total intake in calories. There 
was a significant reduction in calories obtained from banana pellets upon haloperidol treatment 
[F(2,12) = 14.46, p < 0.05]. Post hoc comparisons revealed that both 0.05 mg/kg (M = 6.00, SEM 
= 1.24) and 0.10 mg/kg (M = 2.66, SEM = 0.53) differed from vehicle (M = 14.72, SEM = 3.08). 
Systemic haloperidol also affected the amount of calories obtained from chow [F(2,12) = 17.72, 
p < 0.001]. Chow consumption after 0.05 mg/kg (M = 24.1, SEM = 2.37) and 0.10 mg/kg (M= 
27.15, SEM= 1.45) was higher than during vehicle conditions (M= 18.51, SEM= 2.15). 
Treatment with haloperidol had no effect on the total amount of calories consumed during the 
PR/Chow task [F(2,12) = 1.31, n.s ]. No differences in total calories were observed between 
vehicle (M = 33.22, SEM = 1.82), mid (M= 30.07, SEM = 2.20), and high doses (M = 29.81, SEM 
= 1.63). When collapsed across all conditions, we found a significant negative correlation (r = -
0.6892, df = 19, p < 0.0005) between lever presses and chow intake, highlighting the overall 
inverse relationship between these two variables.  
 
 
 
Figure 1.   Behavioral Effects of dopamine D2 receptor antagonist haloperidol on the 
PR/Chow Task. Animals received IP haloperidol (0.00 mg/kg, 0.05 mg/kg, and 0.10 mg/kg) and 
were tested on the PR/Chow procedure. All data are presented as Means ± SEM. Both doses of 
  
haloperidol decreased A) breakpoint, B) number of lever presses, C) number of reinforcers, and 
increased D) chow intake (in grams).  * p < 0.05 compared to 0.00 mg/kg.  
 
3.3 Experiment 2: Effects of Systemic Naloxone on PR/Chow Responding  
 
 The continued stability on the PR/Chow task across both pharmacological agents was 
assessed by comparing breakpoints, lever presses, number of reinforcers earned, and chow intake 
for haloperidol vehicle and naloxone vehicle treatments. Paired t-tests revealed no significant 
differences between haloperidol and naloxone treatment on breakpoints [t(6) = 0.42, n.s], lever 
presses [t(6) = 0.39, n.s], number of reinforcers earned [t(6) = 0.12, n.s], or chow intakes [t(6) = 
0.72, n.s].  
A one-way repeated ANOVA (factor: naloxone dose) showed that naloxone decreased 
breakpoints [F(2,12) = 5.03, p < 0.05, see Figure 2A]. Follow up Tukey tests revealed that the 
3.0 mg/kg (M = 3.00, SEM = 0.44) dose differed (p < 0.05) from saline (M = 5.71, SEM = 1.30). 
Breakpoints in the 1.5 mg/kg condition (M = 3.42, SEM = 0.57) did not differ from any other 
treatment. There was a trend towards statistical significance (p = 0.06) for naloxone’s effect on 
lever pressing measures [F(2,12) = 3.40, n.s., see Figure 2B]; number of lever presses for 
vehicle, mid, and high doses were (M=352.14, SEM = 150.04), (M =110.43, SEM = 38.68), (M = 
87.29, SEM = 19.83), respectively. Opioid receptor antagonism attenuated the number of 
reinforcers earned [F(2,12) = 4.46, p < 0.05, see Figure 2C], with Tukey’s test revealing that 3.0 
mg/kg (M = 39.00, SEM = 6.63) differed (p < 0.05) from vehicle (M = 78.29, SEM = 20.35), and 
that banana pellet attainment at the 1.5 mg/kg (M = 43.71, SEM = 8.82) dose did not differ from 
any other condition. ANOVA showed no effect of naloxone on chow intake [F(2,12) = 0.24, n.s., 
see Figure 2D] at any of the doses tested (M = 6.57, SEM = 1.10; M = 6.76, SEM = 0.90; M = 
6.99, SEM = 0.76 for saline, 1.5 mg/kg, and 3.0 mg/kg, respectively).  
Effects of naloxone treatment on number of banana pellets, chow, and total intake, in 
calories were also analyzed. ANOVA revealed a trend toward significance (p = 0.06) regarding 
naloxone’s effects on banana-pellet intake [F(2,12) = 4.46, n.s ]. Energy obtained from banana-
flavored pellets for vehicle, mid, and high doses was (M = 13.74, SEM = 3.37), (M= 7.67, SEM = 
1.55), (M = 6.85, SEM = 1.16). Naloxone had no effect on the amount of calories obtained from 
consuming chow [F(2,12) = 0.24, n.s]. Chow consumption under vehicle (M = 20.17, SEM = 
3.37), 1.5 mg/kg (M = 20.74, SEM = 2.77), 3.0 mg/kg (M = 21.45, SEM= 2.319) did not differ. 
One-way ANOVA showed that naloxone decreased total caloric intake [F(2,12) = 4.73, p < 
0.05].  
 
  
 
 
Figure 2.  Behavioral Effects of Opioid Receptor Antagonist Naloxone on PR/Chow Task. 
Rats received IP injections of naloxone (0.00, 1.5 mg/kg, and 3.0 mg/kg) 30 minutes before 
testing. Data are represented as Means ± SEM. Naloxone (3.0 mg/kg) decreased A) breakpoint 
and C) number of reinforcers, but had no effect on B) number of lever presses and D) chow 
intake. * p < 0.05 relative to 0.0 mg/kg dose.  
 
3.4 Experiment 3: Effects of Systemic Haloperidol on Food Intake with No Effort  
 
 All rats went through extensive preference training in order to ensure stability. In addition 
to the criterion set by our laboratory, stability was assessed using a 2 (food type) x 4 (session) 
repeated measures ANOVA over the last 4 days of baseline training. There was no main effect of 
time [F(3,18) = 2.272, n.s], but there was a main effect of food type [F(1,6) = 27.27, p < 0.05] 
such that animals preferred to consume banana pellets to regular lab chow. The interaction 
between the two factors was also not significant [F(3,18) = 0.1813, n.s]. 
 A 2 (Dose) x 2 (Food Type) repeated measures ANOVA was used to determine the 
effects of systemic haloperidol on food intake and preference under free-feeding conditions. 
ANOVA revealed no significant main effect of dose [F(1,6) = 4.66, n.s], a main effect of food 
type [F(1,6) = 70.01, p < 0.05 ], with no significant interaction found [F(1,6) = 0.7109, n.s]. 
Banana pellet consumption was (M = 8.36, SEM = 0.65) and (M = 5.56, SEM = 1.425) under 
  
vehicle and 0.10 mg/kg haloperidol, respectively. Chow consumption was (M = 3.13, SEM = 
0.44) and (M = 1.50, SEM = 0.52) under vehicle and 0.10 mg/kg haloperidol, respectively.  
The data was also analyzed by converting banana pellet intake and chow into calories. 
ANOVA showed no main effect of dose [F(1,6) = 4.4, n.s], a significant main effect of food type 
[F(1,6) = 76.00, p < 0.001], and no significant interaction [F(1,6) = 1.16, n.s]. Banana pellet 
consumption was (M =32.62, SEM = 2.54) and (M = 21.70, SEM = 5.56) under vehicle and 0.10 
mg/kg haloperidol, respectively. Chow consumption was (M = 9.61, SEM = 1.36) and (M = 4.58, 
SEM = 1.60) under vehicle and 0.10 mg/kg haloperidol, respectively. 
 
 
Figure 4. Effects of Systemic Haloperidol Administration on Food Intake and Preference. 
Rats received IP haloperidol 50 minutes before testing. Intake is presented as Means ± SEM. 
Haloperidol had an effect on intake without affecting overall preference.  
 
3.5 Experiment 4: Effects of Naloxone on Food Intake with No Effort 
  
 We tested the stability of intakes during the no effort task during haloperidol and 
naloxone treatments. Paired t-tests showed no differences in banana pellet [t(6) = 1.65, n.s], 
chow[t(6) = 1.18, n.s], or total intakes [t(6) = 1.71, n.s] across the haloperidol vehicle and 
naloxone vehicle treatments.  
The effects of naloxone on free food consumption were assessed with a 2 (Dose) x 2 
(Food Type) repeated measures ANOVA, which revealed a main effect of dose [F(1,6) = 19.12, 
p < 0.05], a main effect of food type [F(1,6) = 25.08, p < 0.05], and a significant interaction 
[F(1,6) = 6.60, p < 0.05]. Post-hoc Tukey’s test revealed that, under vehicle conditions, rats 
preferred (p < 0.005) banana-pellets (M = 12.44, SEM = 2.22) compared to chow (M = 2.63, 
SEM = 0.93). Naloxone (3.0 mg/kg) significantly decreased (p < 0.05) banana pellet intake (M = 
4.51, SEM = 0.91) compared to its vehicle counterpart. In contrast, naloxone appeared to have no 
effect on chow consumption. Intakes of chow after naloxone administration (M = 2.87, SEM = 
0.56) did not differ from chow intakes under the vehicle condition (M = 2.63, SEM = 0.93). The 
  
magnitude of naloxone’s effect was large enough to attenuate banana pellet-preference in drug 
treated animals.  
 When analyzed in terms of calories consumed, a 2 (Dose) x 2 (Food Type) repeated 
measures ANOVA showed a main effect of dose [F(1,6) = 17.08, p < 0.05], a main effect of food 
type [F(1,6) = 35.33, p < 0.001], and a significant dose x food type interaction [F(1,6) = 7.29, p 
< 0.05]. Follow up Tukey’s test showed that animals consumed more banana pellets (M = 48.54, 
SEM = 7.31) than chow (M = 8.10, SEM = 2.40) under vehicle conditions. Naloxone decreased 
banana pellet intake (M = 17.65, SEM = 2.99) selectively, such that there was no difference 
between that and chow (M = 8.80, SEM = 1.45).  
 
 
 
Figure 5.  Effects of Systemic Naloxone Administration of Food Preference.  Rats received 
IP injections of Naloxone (0.0 mg/kg and 3.0 mg/kg) 30 minutes before testing. Data are 
represented as Means ± SEM. Banana pellet intake was greater than chow in the saline solution. 
# p < 0.05 relative to 0.0 mg/kg banana pellet intake. Naloxone also decreased banana pellet 
intake and eliminated preference. * p < 0.05 compared to 0.0 mg/kg banana pellets intake 
 
3.6 Baseline Food Intakes Under Conditions of Effort and No-Effort  
 
 We compared the intakes of animals during baseline training in both tasks in order to 
determine whether there were differences in the amount of food consumed as a function of test 
type. A 2 (Test Type) x 2 (Food Type) ANOVA revealed no significant effect of food type 
[F(1,6) = 2.47, n.s]. There was a main effect of test type [F(1,6) = 15.17, p < 0.05] and a 
significant food and test type interaction [F(1,6) = 132.3, p < 0.0001]. Planned comparisons 
showed intakes of chow differed as a function of test type, (p < 0.05), as did banana pellet 
consumption (p < 0.05). Similar results were found when consumption was converted into 
caloric units. ANOVA revealed a main effect of food type [F(1,6) = 7.27, p < 0.05, see Table 1], 
a main effect of test type [F(1,6) = 33.55, p < 0.05], and a significant interaction [F(1,6) = 119.7, 
  
p < 0.001]. Follow up planned comparisons disclosed that chow and banana consumption 
differed as a function effort (p < 0.05, p < 0.001), respectively. Dependent measures t-tests found 
total intakes differed between tests of effort and no effort in both grams [t(6) = 3.895, p < 0.05, 
2-tailed, see Table 1] and calories [t(6) = 5.792, p < 0.05, 2-tailed].  
 
Unit  Test Type  Banana  Chow  Total  
  Mean  SEM Mean  SEM Mean  SEM 
Grams         
 Effort  3.85* 0.97 7.17 †  
 
1.04 11.02‡ 0.68  
 
 No Effort 11.59 0.96 3.15 0.61 14.76 0.60 
Calories        
 Effort 15.00* 3.81 20.89 †  
 
2.82 35.89‡ 2.42  
 
 No Effort 45.28 3.75 9.66 1.88 54.96 2.54 
 
Table 1. Food intakes by food and test type during baseline training 
Food preference differed depending on the type of test that was conducted. Data are presented as 
Means ± SEM. * p < 0.05 in comparison to banana pellet intake in no effort group. † p < 0.05 in 
comparison to chow intake in no effort group. ‡ p < 0.05 in comparison to total intake in no 
effort group. 
 
4. Discussion  
 
 The present experiments evaluated the behavioral effects of systemic administration of 
dopamine and opioid receptor antagonists on cost/benefit decision-making and food preference 
using tasks with differing levels of effort. Experiment 1 demonstrated that the DA D2 receptor 
antagonist haloperidol, at both doses tested, decreased the breakpoint, number of lever presses, 
number of reinforcers obtained, and increased intake of freely available laboratory chow. Our 
results are in line with previous work that has carefully described the role of DA mechanisms on 
this lever pressing and chow feeding task [52,53,58]. DA antagonism and striatal depletions by 
6-OHDA or tetrabenazine have been shown to decrease measures of lever pressing while 
resulting in compensatory increases in chow intake. The focus of the present experiment, 
however, was not on DA signaling per se, but rather, to replicate previous findings in order to 
better understand the potentially dissociated effects of opioid signaling on food preference and 
decision-making.  
 The nonselective opioid receptor antagonist naloxone produced effects that differed 
slightly from those of haloperidol in Experiment 1. Naloxone, at the highest dose tested (3.0 
mg/kg), decreased breakpoint, number of reinforcers obtained, and marginally decreased the 
number of lever presses. In contrast to the haloperidol treatment, there was no effect on free 
chow intake. To our knowledge, no work has been done investigating the effects of opioid 
antagonism on food motivation using this decision-making task, but previous results from our 
laboratory suggest similar effects can be seen across different schedule requirements [48]. We 
have found that systemic naloxone also decreases lever pressing for palatable pellets when an 
FR5/chow schedule of reinforcement is used (without causing any alterations to free chow 
consumption), suggesting that the motivational effects of opioid receptor antagonism on food 
  
intake are consistent and can be replicated across a number of different schedules of 
reinforcement. In addition to extending previous results from our laboratory, the data from 
Experiment 2 are also consistent with research showing that opioid agonists increase, while 
opioid receptor antagonists decrease, responding on conventional operant tasks across a number 
of ratio schedules and reinforcer types [33,38,47,54].  
Experiments 3 and 4 were carried out in order to determine the effects of haloperidol and 
naloxone on food intake and preference when no effort is involved. In this task, animals had free 
access to both banana pellets and laboratory chow within the operant chamber. We found that 
systemic administration of haloperidol had no significant effect on total food intakes or 
preference in these experiments. The effects of DA antagonism are in line with previous studies 
suggesting that this neurotransmitter does not participate in general food preference [59]. By 
contrast, opioidergic antagonism caused highly selective reductions in food intake by only 
affecting banana-pellets. The magnitude of these effects was large enough such that, under 
naloxone, there was no clear preference for either food type. Our experiments converge with 
lines of preclinical and clinical data suggesting the EOS mediates aspects of hedonic feeding 
[10,16,19,20,23,29,30]. 
A question that arises from our data is whether the results of our experiments were due to 
haloperidol and naloxone acting on central mechanisms that regulate appetite. Our own data, in 
conjunction with that of others, argues against this being the sole contributor to our results. In 
Experiment 1, DA receptor antagonism decreased lever pressing for banana pellets, and by 
extension, consumption of this food type. However, these changes were followed by 
compensatory increases in free chow intake, suggesting that general appetite was not reduced. 
This idea is further strengthened by the fact that administration of haloperidol during the 
PR/Chow task had no effect on the animals’ total caloric intake in this task. Haloperidol appears 
to increase the cost associated with lever pressing, and results in animals reallocating their 
behavior from palatable pellets to the less costly alternative food source, but overall consuming 
similar amounts of food. Furthermore, appetite manipulations have been shown to produce 
different effects from those observed in both the haloperidol and naloxone experiments. Pre-
feeding or administration of appetite suppressants do not increase chow intake at the doses that 
reduce lever pressing. Rather, these manipulations suppress both operant responding and free 
chow intake [53,59,60].  
Previous findings by Randall et al. (2012) using Sprague Dawley rats showed that 0.05 
mg/kg of haloperidol had no effect on lever pressing or chow intake, and 0.10 mg/kg decreased 
lever pressing for banana pellets (without altering chow consumption) [53]. In both our studies 
and those by Randall et al., freely available chow intake either increased or was unaffected by 
haloperidol. The present results showed reductions in lever pressing and concurrent increases in 
chow intake at the 0.05 mg/kg dose, which seems to suggest that Long Evans rats may be more 
sensitive to the pharmacological effects induced by haloperidol. Generally, DA antagonism has 
little to no effect on free feeding at the same doses that suppress lever pressing [59,61]. These are 
findings we replicate in the current study. In Sprague Dawley rats, higher doses than those tested 
here (0.15 mg/kg) also caused reductions in free food intake, but analyses of feeding 
microstructures have shown that they are associated with motor impairments that physically 
prevent animals from consuming food[62]. Because our routes of administration were i.p., we 
cannot fully exclude motor impairments as a factor that contributed to our results. However, 
there are several indications suggesting that they were not the key underlying cause of banana 
pellet intake suppression in Experiment 1. The same dose of haloperidol (0.10 mg/kg) that 
  
reduced lever pressing on the PR/Chow task also produced significant compensatory increases in 
chow intake and had no significant effect on intakes of either food type in the no effort condition. 
This indicates that animals’ ability to interact and consume food, in general remained intact.  
As with the results from the haloperidol treatments, the effects of naloxone cannot be 
entirely understood as a consequence of appetite modification. While some effects on primary 
motivation are possible, this does not appear to be the main variable affected. Opioid receptors 
are localized throughout hypothalamic brain sites that modulate homeostasis [55,63].  It should 
be noted, however, that Experiment 2 still differs from what has been observed with appetite 
manipulations, which decrease lever pressing and chow intake on the PR/Chow task and 
suppress consumption of both food options in no-effort conditions. In both Experiments 2 and 4, 
naloxone’s effects were sensitive to the palatability of the reinforcer, selectively altering 
consumption of the tastant that animals preferred in effort-free conditions, and not intake in 
general. In line with this are previous studies suggesting that while high doses of opioid 
antagonists can decrease intakes of bland foods like water and laboratory chow, their effects are 
more pronounced on sweet tastants like saccharin and sucrose [64]. In addition to taste, 
homeostatic state also appears important for opioid modulation of palatable food intake. The 
anorexigenic effects produced by opioid receptor antagonism are more pronounced in sated than 
food deprived animals, further evidencing the hypothesis that opioids can regulate reward-related 
feeding that occurs outside caloric needs [38,47].  
A second alternative contributor to our results is that administration of the first 
pharmacological agent in each task might have somehow contributed to the results of the next 
task. To elaborate, the possibility exists that haloperidol injections affected the results of 
naloxone experiments during the PR/Chow task, and vice versa on the no effort task. We argue 
that this explanation cannot fully account for our results for a number of reasons. First, the order 
of pharmacology was counterbalanced across our behavioral experiments. Animals were tested 
first with haloperidol on the PR/Chow task and with naloxone initially during the no effort 
condition in order to prevent this from being an underlying factor. In addition, during our testing, 
animals always had at least two days off from pharmacology within each drug and at least a 
week off between drugs to allow any compound to be fully expelled from their systems. Given 
the short half-lives of both naloxone and haloperidol [56,57], prolonged drug effects or 
interactions are unlikely to account for our results. On days in which drug testing did not occur, 
animals continued their baseline training, during which behavior remained stable and comparable 
to each vehicle condition [own observations, unpublished]. Our own statistical analyses between 
naloxone and haloperidol vehicles on each task revealed no differences in performance, 
suggesting that one drug was not likely affecting any subsequent results.  
To our knowledge, this is the first time that opioid regulation of cost/benefit decision-
making has been explored in rodents and our results indicate a role for this neurotransmitter 
system in these processes. It is known that cost/benefit decision-making involves the interaction 
of a wide network of neuroanatomical and neurochemical systems that includes DA, GABA, and 
glutamate signaling interactions within the VTA, NAc, VP, BLA, ACC, and mediodorsal 
thalamus [65–67]. The precise manner in which the EOS fits within this circuitry still remains to 
be fully determined, but there is evidence that mu-opioid receptor signaling within the NAc, VP, 
and BLA might be involved. Naloxone is generally regarded as a relatively nonselective opioid 
receptor antagonist, but research has shown that at low doses, its effects are primarily mediated 
through mu receptors [68]. These receptors are highly localized within the NAc, VP, and BLA, 
and their activities have been previously shown to affect both hedonic and motivational 
  
processes related to food consumption [12,19,22,26,28,34,35,69]. Future research focusing on 
central manipulations will prove fruitful to our understanding of this topic.  
  
5. Conclusions  
 In summary, DA antagonist haloperidol reduced breakpoint, lever presses, and number of 
reinforcers earned while increasing chow intake on the PR/Chow task. In contrast, Naloxone 
decreased breakpoints, and number of reinforcers earned without affecting free chow intake. 
Haloperidol might be reducing responding on the PR/Chow test by affecting motivational 
mechanisms related to effort exertion. By contrast, naloxone’s effects on this task seem to be 
multifaceted; the EOS appears to affect motivational mechanisms related to effort, and also those 
that mediate palatability and hedonic processing. Opioid receptor antagonism might be reducing 
the palatability of preferred foods such as high sucrose banana-flavored pellets, which in turn 
reduces an organism’s willingness to work to obtain such foods. These experiments are 
important for understanding how brain circuitry involved in food motivation and decision-
making might become dysregulated during pathologies of eating. In line with the clinical 
literature, our studies indicate a role for DA and EOS mechanisms in regulating the motivation to 
work for and consume foods. Dysregulation to these systems might produce the compulsive-like 
patterns of food consumption and impaired decision-making seen during disorders like bulimia 
nervosa and binge eating disorder [70–74]; they may be responsible for generating increased 
hedonic responses derived from consuming palatable foods, the development of obsessive 
desires/cravings to consume foods, or both. 
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